Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
- 1 March 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (3), 233-240
- https://doi.org/10.1038/nrd1037
Abstract
The process of early clinical drug development has changed little over the past 20 years despite an up to 40% failure rate associated with inappropriate drug metabolism and pharmacokinetics of candidate molecules. A new method of obtaining human metabolism data known as microdosing has been developed which will permit smarter candidate selection by taking investigational drugs into humans earlier. Microdosing depends on the availability of two ultrasensitive 'big-physics' techniques: positron emission tomography (PET) can provide pharmacodynamic information, whereas accelerator mass spectrometry (AMS) provides pharmacokinetic information. Microdosing allows safer human studies as well as reducing the use of animals in preclinical toxicology.Keywords
This publication has 22 references indexed in Scilit:
- High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography–tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2003
- Integration of virtual and high-throughput screeningNature Reviews Drug Discovery, 2002
- High-throughput crystallography for lead discovery in drug designNature Reviews Drug Discovery, 2002
- Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the techniqueXenobiotica, 2001
- Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humansEuropean Journal of Pharmaceutical Sciences, 2000
- Allometric issues in drug development†Journal of Pharmaceutical Sciences, 1999
- Recombinant yeast in drug metabolismToxicology, 1993
- A method of studying pharmacokinetics in man at picomolar drug concentrations.British Journal of Clinical Pharmacology, 1991
- Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA.Proceedings of the National Academy of Sciences, 1990
- Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).British Journal of Clinical Pharmacology, 1988